Eli Lilly & Co. LLY
$1152.44
+1.28%
at last close
Market Cap$1.03 trillion
P/E Ratio38.69
Div Yield0.60%
Volume1.90M
52-Week Range
$655.10$1292.65
Analyst Ratings
- Consensus
- Buy — 18 Buy · 1 Hold · 1 Sell (20 analysts)
- Avg. Price Target
- $1313.65 (+14.0% upside)
Key Stats
- Today's Range
- $1138.26 – $1159.75
- 50-Day Range
- $1109.15 – $1292.65
- 52-Week Range
- $655.10 – $1292.65
- Volume
- 1.90 million shs
- Average Volume
- 2.40 million shs
- Market Cap
- $1.03 trillion
- P/E Ratio
- 38.69
- Dividend Yield
- 0.60%
Valuation
- P/E Ratio
- 38.69
- Price / Book
- 30.32
- Price / Sales
- 12.89
Dividend
- Dividend Yield
- 0.60%
- Annual Dividend
- $6.92
- Payout Ratio
- 23.23%
- Ex-Dividend Date
- 2026-08-14
Short Interest
- Short Interest
- 1.29%
- Days to Cover
- 5.12
Financials (TTM)
- Revenue
- $79.67 billion
- Net Income
- $26.71 billion
- Net Margin
- 33.53%
- Return on Equity
- 78.84%
- Debt-to-Equity
- —
About Eli Lilly & Co.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Related Stocks
Compare head-to-head: LLY vs JNJ·LLY vs ABBV·LLY vs ABT·LLY vs PFE
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.